23 results about "Diamine oxidase" patented technology

The present invention relates to functional foods and dietary supplements comprising a specific diamine oxidase (DAO) enzyme derived from Glutamicibacter halophytocola, uses of said enzyme and respective methods for the production of biogenic amine-depleted products, uses of said enzyme as a biosensor for the analysis of one or more biogenic amine(s), as well as said enzyme for use in medicine, in particular for use in the prevention or treatment of a condition or disease that is associated with increased levels of biogenic amines.

The invention discloses an Escherichia coli recombinant strain for producing 5-aminovaleric acid and application of the Escherichia coli recombinant strain. The invention relates to the technical field of biology, in particular to engineering bacteria for producing 5-aminovaleric acid and a preparation method of the 5-aminovaleric acid. Compared with a starting strain escherichia coli BL21, the recombinant escherichia coli has the expression of a gene sequence gamma-aminobutyraldehyde dehydrogenase abD gene, a lysine decarboxylase cadA gene and a butanediamine oxidase puO * gene; a gabT gene, a gabD gene, a gabP gene and a cadB gene on a genome of the escherichia coli BL21 are knocked out; a potE gene and a katE gene are integrated on a genome of the escherichia coli BL21. After the strain is used, the yield of 5-aminovaleric acid and derivatives can reach up to 50-192 g / L. The recombinant bacterium can be used for providing raw materials with lower cost for industries such as textiles, electronics, bioplastics, medicines and the like.

A collagen-boosting supplement that contains at least 4, optionally at least 10, collagen building block amino acids and is substantially free of histidine. The building block amino acids may be selected from: Glycine, L-Proline, L-Hydroxyproline, L-Glutamic Acid, L-Alanine, L-Arginine, L-Aspartic Acid, L-Serine, L-Leucine, L-Lysine, L-Hydroxylysine, L-Valine, L-Phenylalanine, L-Threonine, L-Isoleucine, L-Methionine, and L-Tyrosine. The supplement may further comprise: vitamin C; one or more mast cell stabilisers which may be selected from: quercetin, molybdenum, bromelain, DAO (diamine oxidase), Urtica Dioica (stinging nettle), Nigella Sativa (black cumin), Zingiber (ginger), Scutellaria baicalensis (Chinese skullcap), Sambucus (Elderberry), Aloe Vera, Syzygium aromaticum (clove), and matcha; one or more collagen-strengthening herbs which may be selected from: Bilberry, Centella, and Astragulus; one or more Glucosaminoglycans (GAGs) which may be selected from: Hyaluronic acid, glucosamine, and chondroitin; one or more antioxidants which may be selected from: astaxanthin and resveratrol; and / or one or more cofactors which may be selected from: zinc, biotin, silicon, manganese, magnesium, Vitamin D, Vitamin A, Vitamin E, and iron. The supplement may be a foodstuff, medicament, nutraceutical, or cosmetic. The supplement may be used to treat hypermobile Ehlers-Danlos syndrome (hEDS) while reducing the likelihood of mast cell degranulation through histamine activation.

The invention discloses lactobacillus plantarum for overexpressing a luxS gene, a microbial preparation and application of the lactobacillus plantarum, and belongs to the technical field of microorganisms. In order to solve the technical problem that excessive biogenic amines are accumulated in a fermented meat product in the prior art, the invention provides lactobacillus plantarum for overexpressing a luxS gene and a microbial preparation containing the lactobacillus plantarum. The lactobacillus plantarum for overexpressing the luxS gene, provided by the invention, has the capability of highly producing signal molecules AI-2 and has the capability of remarkably improving the activities of diamine oxidase and polyketide oxidase; the lactobacillus plantarum overexpressing the luxS gene and the microbial preparation containing the lactobacillus plantarum can be used as a leavening agent for reducing biogenic amine to be applied to production of fermented meat products, the content of biogenic amine in the air-dried sausages can be effectively reduced, and the quality and safety of the air-dried sausages are improved.

The invention relates to application of a biomarker diamine oxidase (DAO) in prediction, diagnosis and treatment of chronic plus acute liver failure (ACLF). The invention also relates to correlation analysis of DAO and ACLF diagnostic markers such as TBIL, INR and the like. On the basis of existing TBIL and INR index models, the DAO index is added, early warning can be conducted on ACLF, complex instruments, equipment and schemes are not needed for DAO concentration detection, the detection period is short, and therefore a new marker is provided for clinical diagnosis and treatment of ACLF, and important clinical significance is achieved.

The invention discloses a high-performance biosensor based on a g-C3N4 / TiO2 heterojunction as well as a preparation method and application of the high-performance biosensor, and belongs to the technical field of biosensing and food safety detection. The sensor is constructed by taking a glassy carbon electrode as a substrate and sequentially modifying a g-C3N4 / TiO2 heterojunction composite material and diamine oxidase (DAO). The g-C3N4 / TiO2 heterojunction is prepared through a one-step calcination method, a type II p-n junction structure is formed, photo-generated charge separation and interface electron transfer are effectively promoted, and the conductivity, catalytic activity and enzyme immobilization capacity of the electrode are remarkably improved. The invention discloses a synergistic mechanism of heterojunction interface enhanced histamine selective adsorption and catalytic reaction through density functional theory calculation. The sensor shows excellent detection performance on histamine: the linearity is good in a range of 0.05-10 mM, and the detection limit is as low as 0.075 M; the selectivity is still higher than 93% in the presence of an interferent with ten times of concentration; when the method is applied to detection of actual samples of beef, mutton, fish and chicken, the adding standard recovery rate is 93.60%-101.8%, and the relative standard deviation is smaller than 5%. The sensor has the advantages of high sensitivity, good selectivity, strong anti-interference capability, good reproducibility and the like, and a reliable new method is provided for rapid and accurate screening of histamine in food.

The invention relates to a biomarker for diagnosing rheumatoid arthritis and application of the biomarker, and belongs to the technical field of biological medicines. The invention finds that the concentration of lipopolysaccharide and diamine oxidase in the plasma of a patient with rheumatoid arthritis (RA) is obviously higher than that of a healthy control group; furthermore, the invention also discovers that three proteins from plasma exosomes, namely phospholipid flip enzyme 1 (PLSCR1), keratin 1 (KRT1) and complement C1Q C chain (C1QC), have a good diagnosis effect on rheumatoid arthritis, and the diagnosis accuracy of rheumatoid arthritis can be remarkably improved by performing combined diagnosis on lipopolysaccharide and diamine oxidase with the three proteins. Therefore, when the biomarker is applied to preparation of RA diagnosis products, a core basis can be provided for accurate diagnosis of RA and generation of a risk assessment system, and the biomarker has transformation application value in the aspects of early diagnosis of RA and screening and accurate prevention and treatment of high-risk groups.

The present invention relates to a recombinant human diamine oxidase (DAO) with reduced glycosaminoglycan binding affinity, said DAO comprising at least one amino acid modification in the glycosaminoglycan (GAG)-binding domain. The present invention further relates to the use of DAO in the treatment of conditions associated with excess histamine, particularly in the treatment of chronic allergic diseases, more particularly in the treatment of anaphylaxis, anaphylactic shock, chronic urticaria, acute urticaria, asthma, hay fever, allergic rhinitis, allergic conjunctivitis, histamine poisoning, headache, atopic dermatitis, inflammatory diseases, mastocytosis, mast cell activation syndrome (MCAS), pre-eclampsia, hyperemesis gravidarum, preterm labor, peptic ulcer, acid reflux, pruritus, and sepsis.

The invention discloses application of a bifidobacterium longum subsp. Infantis CCFM1426 strain and vitamin A in preparation of a medicine for improving the physiological activity of the vitamin A and / or relieving colitis and / or xerophthalmia symptoms. The probiotic agent provided by the invention comprises a bifidobacterium longum subsp. Infantis CCFM1426 strain with the preservation number of GDMCC No.65152 and vitamin A, and can be used for improving the retinoic acid level in the colon of a mouse with ulcerative colitis; the diamine oxidase level, the intestinal fatty acid binding protein level and the lipopolysaccharide binding level in serum of mice with ulcerative colitis are reduced; the corneal injury, basal vacuolation and conjunctival goblet cell injury of the xerophthalmia mice are relieved; the level of retinoic acid in serum of the dry-eye mouse is improved; and the levels of IL-6, IL-17 and TNF-alpha in serum of dry eye mice are reduced. Therefore, the probiotic agent disclosed by the invention has a relatively great application prospect in preparation of products for supplementing vitamin A and preventing and / or treating ulcerative colitis and xerophthalmia.

The invention discloses an application of a reagent containing multi-copper oxidase in reducing the biogenic amine content of a fermented meat product, recombinant multi-copper oxidase is obtained through a genetic engineering technology, and the multi-copper oxidase is developed into an enzyme reagent for degrading biogenic amine in Sichuan sausages. Results show that the addition of the reagent containing the multi-copper oxidase and the diamine oxidase has no influence on the eating quality and the sensory quality of the Sichuan sausages, in terms of the biogenic amine content, after the reagent is added, the degradation rates of histamine, tyramine, cadaverine and putrescine are at least 49.63%, 38.51%, 38.26% and 35.40%, and the degradation rates of the reagent containing the multi-copper oxidase and the diamine oxidase are at least 49.63%, 38.51%, 38.26% and 35.40%. The reagent provided by the invention has a good degradation effect on four main biogenic amines in Sichuan sausages.

The invention discloses a preparation method for reducing biogenic amine in red intestines by using lactobacillus plantarum diamine oxidase. The preparation method comprises the following steps: culturing lactobacillus plantarum SH7, extracting and purifying the diamine oxidase and applying the diamine oxidase to the red intestines. High-activity enzyme powder is obtained through ammonium sulfate salting-out and anion exchange chromatography and added into the sausage raw material, biogenic amine is effectively degraded, the safety of the sausage is improved, and the product quality is not affected. The method is simple in process and suitable for industrial production, and provides a new way for biogenic amine control of fermented meat products.

The invention provides application of astaxanthin in preparation of medicines for preventing and treating intestinal dysfunction and intestinal flora imbalance related to severe acute pancreatitis or repairing intestinal mucosal barrier. In-vivo experiments prove that the astaxanthin can significantly improve SAP-induced intestinal barrier injury, reduce the activity of serum diamine oxidase (DAO), repair a jejunum villus structure and up-regulate the expression of tight junction proteins (ZO-1, Occludin and Claudin); the mechanism relates to inhibition of local inflammatory response and oxidative stress, and specific correction of intestinal flora disorder, including recovery of proportion balance of phylum firmicalis and bacteroides, and improvement of abundance of beneficial bacteria such as lactobacillus murine and ruminococcus; the invention provides a new strategy for clinical treatment of SAP complicated with intestinal failure.

The present invention relates to a method of preparing an incubation medium for histochemical analysis of diamine oxidase in a native tissue sample. In a first step, phenazine methosulfate, preferably 0.5 to 1.0 mg phenazine methosulfate; an aqueous tetrazolium salt solution at a concentration of 0.01 to 0.2 wt. % and in a molar ratio of tetrazolium salt to phenazine methosulfate of 2:1 to 1 :2, preferably 1.5 to 2.5 mL 0.1 wt. % nitro blue tetrazolium chloride solution; an aqueous substrate solution comprising at least one D-amino acid at a concentration of 0.4 to 1.2 M and in a molar ratio of D-amino acid to phenazine methosulfate of 10:1 to 230:1, preferably 0.1 to 0.3 mL substrate solution comprising 1 M D-alanine and 0.5 M D-phenylalanine; and optionally, an aqueous cyanide salt solution at a concentration of 0.01 to 0.2 M and in a molar ratio of cyanide salt to phenazine methosulfate of 40:1 to 1 :4, preferably 0.1 to 0.3 mL 0.1 M potassium cyanide solution are mixed. In a second step, the incubation medium is illuminated for 1 to 10 min. to form an incubation medium for histochemical analysis of diamine oxidase in the native tissue sample.

The invention discloses a preparation method and application of an armillariella tabescens-wolfberry bidirectional fermentation product, and belongs to the technical field of microbial fermentation and treatment of chemotherapy-induced intestinal mucosal lesion. The armillariella tabescens-wolfberry bidirectional fermentation product is prepared from armillariella tabescens mycelia and a basic culture medium added with wolfberry through a bidirectional fermentation technology. Functional evaluation is performed by constructing a 5-FU induced colon cancer tumor-bearing mouse intestinal mucosa injury model, and experimental results show that the armillariella-wolfberry bidirectional fermentation product can remarkably relieve weight loss and diarrhea symptoms of model animals caused by chemotherapy, remarkably reduce the level of diamine oxidase (DAO) in serum and effectively improve intestinal mucosa injury.

The invention relates to a method for the production of a stabilised lyophilisate with plant diamine oxidase (DAO), comprising the following steps: providing DAO-containing plants or DAO-containing parts thereof; homogenising the DAO-containing plants or DAO-containing parts thereof in aqueous solution in order to obtain an aqueous homogenised product; adding (a) a sugar or sugar alcohol and (b) an amino acid as stabiliser; and lyophilising the aqueous homogenised product or a DAO-containing fraction thereof in the presence of the stabiliser. The invention also relates to a lyophilisate obtained according to this method, and to a solid pharmaceutical dosage form for oral administration, containing said lyophilisate. This dosage form is intended for therapeutic use, preferably in the treatment of histamine-induced disorders, or can be used as a food supplement or dietetic food.

Provided are recombinant adeno-associated virus (rAAV) vectors, methods of treating a condition (e.g., an ocular condition), pharmaceutical compositions, and other compositions and methods, in which the rAAV vector comprises a polynucleotide encoding diamine oxidase (DAO1). Methods of treatment may include administration to the lacrimal gland.

This invention relates to a biomarker for diagnosing rheumatoid arthritis (RA) and its application, belonging to the field of biomedical technology. This invention discovered that the concentrations of lipopolysaccharide (LPS) and diamine oxidase (DAO) in the plasma of RA patients are significantly higher than those in healthy controls. Furthermore, this invention also found that three proteins derived from plasma exosomes—phospholipid invertase 1 (PLSCR1), keratin 1 (KRT1), and complement C1QC chain (C1QC)—have good diagnostic effects on RA. Combining LPS and DAO with these three proteins can significantly improve the diagnostic accuracy of RA. Therefore, applying the biomarker of this invention to the preparation of RA diagnostic products can provide a core basis for the accurate diagnosis of RA and the generation of risk assessment systems, and has translational application value in the early diagnosis of RA and the screening and precise prevention and treatment of high-risk groups.

The invention relates to application of a protein marker in preparation of a rheumatoid arthritis diagnostic kit, and belongs to the technical field of biological medicines. The protein marker for diagnosing rheumatoid arthritis is screened from plasma and plasma exosomes, specifically, the AUC of C4BPA from the plasma exosomes is 0.878, the specificity is as high as 94.1%, and the protein marker has remarkable advantages in the aspect of excluding non-RA people. C4BPA and diamine oxidase (DAO) from plasma have good diagnostic value in the independent diagnosis of RA, and the AUC is 0.844 and 0.946 respectively. The AUC of the combined diagnosis model constructed based on the plasma C4BPA and the plasma DAO is improved to 0.965. Therefore, the protein marker provided by the invention has an accurate diagnosis effect on rheumatoid arthritis, and has a good transformation application prospect for auxiliary diagnosis and risk assessment of RA.

The present application relates to the application of protein markers in the preparation of a diagnostic kit for rheumatoid arthritis, and belongs to the technical field of biological medicine. The present application screens protein markers for diagnosing rheumatoid arthritis from plasma and plasma exosomes. Specifically, the AUC of C4BPA from plasma exosomes is 0.878, and the specificity is as high as 94.1%, which has a significant advantage in excluding non-RA populations. C4BPA and diamine oxidase (DAO) from plasma both have good diagnostic value in the independent diagnosis of RA, with AUCs of 0.844 and 0.946, respectively. The combined diagnostic model based on plasma C4BPA and plasma DAO has an AUC of 0.965. Therefore, the protein markers of the present application have accurate diagnostic effects on rheumatoid arthritis, and have good application prospects for the auxiliary diagnosis and risk assessment of RA.

The present invention relates to functional foods and dietary supplements comprising a specific diamine oxidase (DAO) enzyme derived from the yeast Yarrowia lipolytica PO1f, uses of said enzyme and respective methods for the production of biogenic amine-depleted products, and said enzyme for use in medicine, in particular for use in the prevention or treatment of a condition or disease that is associated with increased levels of biogenic amines.

The present invention relates to diamine oxidase (DAO) for use in the treatment and / or prevention of sleep and circadian rhythm disorders, and cognitive impairment associated thereto.

The application provides a diamine oxidase detection probe and a kit. The diamine oxidase detection probe with the chemical structure shown in formula (I) can realize fluorescence color development, has an absorption peak value in the range of 592-602 nm, and the absorption peak value is near 596 nm. The diamine oxidase can oxidize the diamine oxidase detection probe shown in formula (I), so that the light absorption in the range of 592-602 nm disappears. The diamine oxidase detection probe with the chemical structure shown in formula (I) is stable in structure and is beneficial to storage. The diamine oxidase detection probe with the chemical structure shown in formula (I) can be applied to diamine oxidase detection. The application provides a detection method for taking the serum diamine oxidase (DAO) level as an early diagnosis index of intestinal mucosal injury.